Press Release

Marsha Stanton, Ph.D., RN, Pernix Therapeutics Executive Director of Medical and Government Affairs, Awarded Prestigious Pain Management Advocacy Award from the American Society for Pain Management Nursing®

MORRISTOWN, N.J., Sept. 16, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, today announced that Marsha Stanton, Ph.D., RN, Executive Director of Medical and Government Affairs, was awarded the prestigious Pain Management Advocacy Award from the American Society for Pain Management Nursing® (ASPMN) at the 2016 ASPMN National Conference, which was held in Louisville, KY, from September 7-10, 2016.

“We are proud of Dr. Stanton’s recognition at the ASPMN national conference, and are very pleased to have someone of her caliber as a member of the Pernix Therapeutics team,” said John Sedor, Chairman and CEO of Pernix Therapeutics.

Nominees for the Pain Management Advocacy Award must demonstrate leadership and outstanding contributions which have influenced public perception, attitudes, and awareness of pain and its management through public education, governmental reform, and/or media exposure compatible with the ASPMN mission and goals. 

Dr. Stanton is nationally recognized for her extensive work in pain management, including clinical practice, public policy and patient education. She is a registered nurse, and obtained her Master of Science in Health & Human Services from Columbia Pacific University and a Ph.D. in Health Education from Glendale University.

About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.

To learn more about Pernix Therapeutics, visit

Zohydro® ER is a registered trademark of Pernix Therapeutics Holdings, Inc.  BeadTek™ is a trademark used by Pernix under license.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Statements including words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “target” or similar expressions are forward-looking statements.  These statements reflect the Company’s current views, expectations and beliefs concerning future events.  These forward-looking statements include statements regarding: planned development activities relating to a next-generation version of Zohydro ER, estimated annualized cost savings and potential for future revenue growth and profitability resulting from the restructuring of our salesforce and the recent management changes, increased usage of our three core products, Treximet, Silenor and Zohydro ER, increased usage of our prescription fulfillment program, Pernix Prescriptions Direct, and improved financial flexibility through a possible restructuring of our debt and other potential alternatives. The inclusion of forward-looking statements should not be regarded as a representation by Pernix that any of its plans will be achieved.  Investors should note that many factors, including the risks and uncertainties inherent in Pernix’s business, as more fully described in Pernix’s filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2015 and subsequent filings with the SEC, could affect the Company’s future financial results and could cause actual results to differ materially from those expressed in forward-looking statements contained in this press release.  The forward-looking statements in this press release are qualified by these risk factors.  These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Investor Relations
Matthew P. Duffy, 212-915-0685
LifeSci Advisors, LLC

Primary Logo

Pernix Therapeutics Holdings, Inc.